findmyKOL
Clinical trialNCT02391545TerminatedPhase 1/PHASE2Interventional

A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)

SponsorSecuraBioEnrollment55CD20+ Follicular Lymphoma
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

21 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Belgium
  • Facility name not stated

    Kortrijk, Belgium

  • Facility name not stated

    Leuven, Belgium

  • Facility name not stated

    Wilrijk, Belgium

France
  • Facility name not stated

    Clermont-Ferrand, France

  • Facility name not stated

    Marseille, France

  • Facility name not stated

    Pessac, France

  • Facility name not stated

    Rouen, France

  • Facility name not stated

    Tours, France

Italy
  • Facility name not stated

    Bologna, Italy

  • Facility name not stated

    Varese, Italy

Spain
  • Facility name not stated

    Badalona, Barcelona, Spain

  • Facility name not stated

    Barcelona, Spain

  • Facility name not stated

    Madrid, Spain

  • Facility name not stated

    Salamanca, Spain

United Kingdom
  • Facility name not stated

    Leeds, United Kingdom

  • Facility name not stated

    London, United Kingdom

United States
  • Facility name not stated

    Los Angeles, California, United States

  • Facility name not stated

    Palo Alto, California, United States

  • Facility name not stated

    Hackensack, New Jersey, United States

  • Facility name not stated

    Rochester, New York, United States

  • Facility name not stated

    Dallas, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Dec 2014
Primary completion
17 Jan 2017
Completion
31 May 2017
Last update posted
28 Sept 2023
Registered enrollment
55
Registry id
NCT02391545

Cross-registrations

EU-CTR / CTIS (EudraCT)2014-005459-13

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.